Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)


clopidogrel / acetylsalicylic acid

This medicine is authorised for use in the European Union.


This document is a summary of the European Public Assessment Report (EPAR) for Clopidogrel/Acetylsalicylic acid Zentiva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel/Acetylsalicylic acid Zentiva.

This EPAR was last updated on 13/11/2019

Authorisation details

Product details
Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)
Agency product number
Active substance
  • clopidogrel
  • Acetylsalicylic acid
International non-proprietary name (INN) or common name
  • clopidogrel
  • acetylsalicylic acid
Therapeutic area (MeSH)
  • Acute Coronary Syndrome
  • Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Sanofi-Aventis Groupe
Date of issue of marketing authorisation valid throughout the European Union
Contact address
54 rue La Boétie
F-75008 Paris

Product information

19/09/2019 Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover) - EMEA/H/C/001144 - WS/1665

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

  • Acute Coronary Syndrome
  • Myocardial Infarction

Assessment history

How useful was this page?

Add your rating
2 ratings